In a preliminary communication (J. Med. Chem. 1989, 32, 11-13) a series of perfluoro-N-[4- (1H-tetrazol-5yl-methy1) phenyllalkanamides (perfluoro anilides I), designed as novel analogues of ciglitazone, were reported to possess oral antidiabetic activity in two genetic animal models of non-insulin-dependent diabeh mellitus (NIDDM): obese (ob/ob) and diabetic (db/db) mice. In this report, the results from a structure-activity relationship (SAR) ...